Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects. by Kraft, Walter K. et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Pharmacology and Experimental
Therapeutics Faculty Papers
Department of Pharmacology and Experimental
Therapeutics
8-1-2016
Effect of Vorapaxar Alone and in Combination with
Aspirin on Bleeding Time and Platelet Aggregation
in Healthy Adult Subjects.
Walter K. Kraft
Thomas Jefferson University, walter.kraft@jefferson.edu
J H Gilmartin
Merck & Co
D L Chappell
Merck & Co
F Gheyas
Merck & Co
B M Walker
Merck & Co
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/petfp
Part of the Pharmacy and Pharmaceutical Sciences Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Pharmacology and Experimental Therapeutics Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For
more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Kraft, Walter K.; Gilmartin, J H; Chappell, D L; Gheyas, F; Walker, B M; Nagalla, S; Naik, U P;
Horrow, J C; Wrishko, R E; Zhang, S; and Anderson, M S, "Effect of Vorapaxar Alone and in
Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects."
(2016). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 73.
http://jdc.jefferson.edu/petfp/73
Authors
Walter K. Kraft, J H Gilmartin, D L Chappell, F Gheyas, B M Walker, S Nagalla, U P Naik, J C Horrow, R E
Wrishko, S Zhang, and M S Anderson
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/petfp/73
CTS Clinical and Translational Science
Citation: Clin Transl Sci (2016) 9, 221–227; doi:10.1111/cts.12405
C© 2016 ASCPT. All rights reserved
ARTICLE
Effect of Vorapaxar Alone and in Combination with Aspirin
on Bleeding Time and Platelet Aggregation in Healthy
Adult Subjects
WK Kraft1, JH Gilmartin2, DL Chappell2, F Gheyas2, BM Walker2, S Nagalla1, UP Naik1, JC Horrow2, RE Wrishko2, S Zhang2
and MS Anderson2,∗
The effect of the protease-activated receptor-1 (PAR-1) antagonist vorapaxar on human bleeding time is not known. This was
a randomized, two-period, open-label trial in healthy men (n = 31) and women (n = 5). In period 1, subjects received 81 mg
aspirin q.d. or a vorapaxar regimen achieving steady-state plasma concentrations equivalent to chronic 2.5 mg q.d. doses, for
7 days. In period 2, each group added 7 days of the therapy alternate to that of period 1 without washout. Bleeding time and
platelet aggregation using arachidonic acid, ADP, and TRAP agonists were assessed. Bleeding time geometric mean ratio (90%
CI) for vorapaxar/baseline was 1.01 (0.88–1.15), aspirin/baseline was 1.32 (1.15–1.51), vorapaxar + aspirin/vorapaxar was
1.47 (1.26–1.70), and vorapaxar + aspirin/aspirin was 1.12 (0.96–1.30). Unlike aspirin, vorapaxar did not prolong bleeding time
compared with baseline. Bleeding time following administration of vorapaxar with aspirin was similar to that following aspirin
alone.
Clin Transl Sci (2016) 9, 221–227; doi:10.1111/cts.12405; published online on 15 June 2016.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THIS
TOPIC?
✔ Aspirin and P2Y12 inhibitors each prolong human bleed-
ing time. The effect of the selective PAR-1 antagonist vora-
paxar on human bleeding time is not known. Vorapaxar
inhibits TRAP-induced ex vivo platelet aggregation but not
ADP- or collagen-induced platelet aggregation, suggesting
that vorapaxar treatment alone may not prolong bleeding
time.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ The present study, conducted in healthy volunteers,
examined the effect of steady-state vorapaxar on bleeding
time compared with therapy-naive baseline. Aspirin was
included as a comparator.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE?
✔ This study adds to our knowledge regarding the human
bleeding time profile of vorapaxar. Unlike aspirin, bleeding
time following vorapaxar was similar to that at baseline.
Bleeding time following vorapaxar with aspirin was similar
to that following aspirin alone.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOL-
OGY AND THERAPEUTICS?
✔ The implications of these findings for clinical sponta-
neous or surgical bleeding await further analyses of clinical
trial data.
Vorapaxar sulfate (ZONTIVITY; hereafter referred to as
vorapaxar) is a first in class antagonist of the protease-
activated receptor-1 (PAR-1), the primary thrombin recep-
tor on human platelets, which mediates the downstream
effects of thrombin in hemostasis and thrombosis. Thrombin-
induced platelet activation has been implicated in a variety of
cardiovascular disorders, including thrombosis, atheroscle-
rosis, and restenosis, following percutaneous coronary inter-
vention. Based on a large, placebo-controlled, phase III study
conducted in 26,449 adult patients, the Thrombin-Receptor
Antagonist in Secondary Prevention of Atherothrombotic
Ischemic Events (TRA 2°P – TIMI 50) trial, vorapaxar admin-
istered in addition to standard of care was approved to
1Thomas Jefferson University, Philadelphia, Pennsylvania, USA; 2Merck & Co., Kenilworth, New Jersey, USA. ∗Correspondence: MS Anderson (matt_anderson
@merck.com)
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reduce the risk of thrombotic cardiovascular events in the
United States and European Union in patients with a history
of myocardial infarction, and, in the United States, also in
patients with peripheral arterial disease.1,2
As an inhibitor of the PAR-1 pathway, vorapaxar specif-
ically blocks thrombin-mediated platelet aggregation.
Although this mechanism of action provides patient benefit
when coadministered with standard of care to reduce the
risk of atherothrombotic complications of coronary artery
disease, the potential exists that bleeding time due to the
inhibition of this hemostatic mechanism may be prolonged.
However, as a selective PAR-1 antagonist, vorapaxar inhibits
thrombin receptor agonist peptide (TRAP)-induced ex vivo
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Figure 1 Study design.
platelet aggregation without affecting ADP- or collagen-
induced platelet aggregation, suggesting that vorapaxar
treatment alone may not prolong bleeding time due to the
continued integrity of these alternative homeostatic path-
ways. The template bleeding time is a reproducible and
sensitive method to measure the processes that form an
initial platelet plug upon external injury to the vasculature.3
Bleeding time assesses platelet function in the context of
damaged skin and microvasculature as well as the inter-
action of platelets with the coagulation and fibrinolytic
system. The present study, conducted in healthy volunteers,
evaluated the potential for steady-state vorapaxar to pro-
long bleeding time compared with therapy-naive baseline
using a standard templated methodology for this assess-
ment. Aspirin was included as a comparator in this study
as it is commonly used as standard of care background
therapy in the patient populations for which vorapaxar is
indicated.
METHODS AND MATERIALS
Subjects
The study enrolled healthy male and female subjects 18 to
65 years of age. Exclusion criteria included: significant intol-
erance to aspirin; anticoagulant therapy; bleeding or spon-
taneous bruising diathesis; or a platelet transfusion within
7 days. All subjects provided written informed consent prior
to participating in the trial.
Study design
This was a randomized, active controlled, parallel group, two-
period, assessor-blinded, open-label trial (identified as Pro-
tocol No. 046). The study design is summarized in Figure 1
and the specific vorapaxar and aspirin doses administered
are shown in Table 1. In period 1, subjects received either
81 mgaspirin once-daily for 7 days (N = 18), or a 7-day
regimen of vorapaxar (N= 18) achieving steady-state plasma
concentrations equivalent to chronic 2.5 mg once-daily
doses. In period 2, each group added 7 days of the ther-
apy alternate to that of period 1, without washout. Subjects
fasted from all food and drink (except water) for at least
4 h prior to all platelet aggregation blood sample collections.
All subjects refrained from consuming high or moderate fat
foods and drinks for at least 8 h prior to platelet aggrega-
tion sample collections. Consumption of low fat foods and
drinks was permitted up to 4 h prior to the platelet aggrega-
tion blood draws. All bleeding time and platelet aggregome-
try operators were blinded to subject allocation, and were not
involved with any other aspects of study conduct that would
allow them to review subject source documents.
The study protocol was reviewed and approved by an inde-
pendent institutional review board (Thomas Jefferson Univer-
sity Institutional Review Board). The study was conducted
in accordance with the guidelines on good clinical practice
and with ethical standards for human experimentation estab-
lished by the Declaration of Helsinki.
Pharmacokinetic assessments
Blood was drawn for vorapaxar pharmacokinetic (PK) anal-
ysis predose on day 1 of each treatment period and at
selected time points through 2 h following the day 7 dose
in period 1 and 24 h following the day 7 dose in period
2. The plasma concentration of vorapaxar was analyzed
by means of ultraperformance liquid chromatography and
tandemmass spectrometry detection using positive ion elec-
trospray. The lower limit of quantitation was 1 ng/mL. The
analytical range was 1–1000 ng/mL. For each vorapaxar
treatment period, the plasma concentration of vorapaxar was
estimated for all subjects at trough (Ctrough) during the last two
administered doses as well as at peak plasma concentration
(Cmax) and 24 h following the day 7 dose (C24).
PHARMACODYNAMIC ASSESSMENTS
Platelet aggregation
Platelet aggregation was assessed three times: predose in
periods 1 (baseline) and 2, and 24 h after the last dose in
period 2. Blood samples for whole blood aggregometry were
collected into BD Vacutainer tubes containing citrate (Bec-
ton Dickenson). Platelet-rich plasma was prepared by cen-
trifuging the anticoagulated whole blood samples and trans-
ferring the platelet-rich plasma layer into a separate tube. The
platelet-rich plasma (225 μL) was transferred to a cuvette
containing a magnetic stir bar. After incubation for 3 min at
37°C, an electrode probe assembly was inserted into the
cuvette. Following establishment of a baselinemeasurement,
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Table 1 Summary of vorapaxar and aspirin doses administered
Treatment
regimen
No. of
patients Period 1a Period 2a
1 18 Vorapaxar alone
• Day 1 am: 7.5 mg vorapaxar single dose
• Day 1 pm: 10 mg vorapaxar single doseb
• Day 2 am: 5 mg vorapaxar single dosea
• Day 2 pm: 7.5 mg vorapaxar single dosea,b
• Days 3–5: 5 mg vorapaxar once-dailya
• Days 6–7: 2.5 mg vorapaxar once-dailya
Aspirin coadministered with vorapaxar
81 mg aspirin coadministered with 2.5 mg vorapaxar, both
once-daily × 7 daysb
2 18 Aspirin alone
81 mg aspirin once-daily × 7 daysa
Vorapaxar coadministered with aspirin
• Day 1 am: 7.5 mg vorapaxar + 81 mg aspirin, single doses
• Day 1 pm: 10 mg vorapaxar single doseb
• Day 2 am: 5 mg vorapaxar + 81 mg aspirin, single dosesa
• Day 2 pm: 7.5 mg vorapaxar single dosea,b
• Days 3–5: 5 mg vorapaxar q.d. + 81 mg aspirin once-dailya
• Days 6–7: 2.5 mg vorapaxar q.d. + 81 mg aspirin once-dailya
aDose(s) on days 2–6 were to be administered approximately the same time as the dose(s) on day 1, ± 2 h.
bThe second (pm) vorapaxar dose on days 1 and 2 was to be administered 12 h ± 2 h after the morning (am) dose.
25 μL of one of the following agonists was added to achieve
the final indicated concentration: adenosine diphosphate
(ADP; 10 μM), arachidonic acid (500 μg/mL), or TRAP-6
(15 μM). Platelet aggregometry was assessed using a
Chrono-Log Model 700 aggregometer (Chrono-Log, Haver-
town, PA, USA). Changes in sample impedance were
recorded for a total of 6 min. A single technician performed
all of the platelet aggregometry assays.
Coagulation parameter assessment
Blood samples for an assessment of coagulation function
were collected prior to day 1 study drug administration in
periods 1 and 2, and 24 h after the period 2 day 7 study drug
administration. Standard measures of coagulation assessed
in this study included prothrombin time (PT) and activated
partial thromboplastin time (aPTT).
Bleeding time
Bleeding time was assessed predose in periods 1 (baseline)
and 2, and 24 h after the last dose in period 2. A blood pres-
sure cuff was placed on the subject’s arm above the elbow
and inflated to 40 mm Hg throughout the procedure. A tar-
get incision site without superficial veins approximately in
the middle of the muscular area of the forearm was selected
and cleansed. A small incision wound of 5-mm length and
1-mm depth was made at the target site with a sterile dis-
posable template bleeding time device (Surgicutt for adults;
International Technidyne Corporation, Edison, NJ, USA).4 A
stopwatch was started at the appearance of the first drop of
blood. The edge of a 3.5” circular filter paper was used to blot
the blood through capillary action by gently touching the drop
every 30 seconds. The wound itself was not disturbed. The
blood pressure gauge was removed once bleeding stopped
spontaneously and a sterile dressing was applied. The
end point was reached when blood could no longer be blot-
ted from the forearm incision. Bleeding times >30 min were
truncated and the measurement reported as >30 min. The
same operator performed the bleeding time test on the same
subject throughout the course of the study.
Statistical analysis
Descriptive statistics were provided for the plasma PK of
vorapaxar at trough during the last two administered doses of
each period, at Cmax after dosing on day 7 of each period, and
24 h after the day 7 dose in each period. Arithmetic mean and
SD based on the raw scale were provided. In addition, the
percent coefficient of variation were also provided and calcu-
lated according to the following formula: 100 × sqrt(exp(s2)
– 1), where s2 is the observed variance on the natural
log-scale.
Bleeding time data were analyzed using a linear mixed
effects model with fixed effect for treatment (baseline,
vorapaxar alone, aspirin alone, and vorapaxar + aspirin).
An unstructured covariance matrix was used to allow for
unequal treatment variances and to model the correlation
between the measurements within each subject using the
REPEATED statement in SAS PROC MIXED. The Kenward
and Roger’s method were used to calculate the DDFM =
KR. The geometric mean ratio (GMR) for bleeding time:
(a) steady-state vorapaxar alone vs. baseline; (b) steady-
state vorapaxar coadministered with steady-state aspirin
compared with steady-state aspirin alone; (c) steady-state
vorapaxar coadministered with steady-state aspirin com-
pared with steady-state vorapaxar alone; and (d) steady-
state aspirin compared with baseline was estimated and a
90% confidence interval (CI) of the GMR was provided. The
prespecified GMR lower and upper equivalence bounds for
these four comparisons were 0.67 and 1.50, respectively.
Assuming a pooled within-subject SD for bleeding time of
0.2637, and if the true GMR for bleeding time of steady-state
vorapaxar alone at period 1, day 7, 24 h vs. baseline was
between 0.82 and 1.21, then a sample size of 36 subjects
in which at least one-half of the sample (N = 18) achieved
steady-state vorapaxar levels would provide 90% probabil-
ity that the 90% CI for this comparison was between 0.67
and 1.50.
For the other PD end points, TRAP-, arachidonic acid
(AA)-, ADP-induced platelet aggregation as well as PT and
aPTT, the same linear mixed effects model described above
for bleeding time was used.
www.wileyonlinelibrary/cts
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Table 2 Plasma PKs of vorapaxar administered alone or with aspirin 81 mg, once-daily for 7 days
Regimen Treatment Period Day No. Ctrough (ng/mL)a Cmax (ng/mL) C24 (ng/mL)b
1 Vorapaxar days 1–7 1 6 18 51.1 (41.0) NA NA
7 18 50.6 (38.8) 67.3 (40.3) 47.9 (39.1)
Vorapaxar coadministered with aspirin days 1–7 2 6 17c 50.9 (27.9) NA NA
7 17c 51.1 (30.9) 55.1 (24.5) 51.0 (31.3)
2 Vorapaxar coadministered with aspirin days 1–7 2 6 18 47.4 (21.2) NA NA
7 18 47.6 (19.0) 54.0 (24.1) 44.1 (21.0)
NA, values are not applicable; PK, pharmacokinetic.
Ctrough, Cmax, and C24 data expressed as geometric mean (% coefficient of variation).
Treatment regimen 1: Vorapaxar for 7 days to steady-state in period 1; aspirin coadministered with steady-state vorapaxar for 7 days in period 2.
Treatment regimen 2: Aspirin for 7 days to steady-state in period 1; vorapaxar coadministered with steady-state aspirin for 7 days in period 2.
aPre-dose (0 h) timepoint. bC24 = Hour 24 post-dose timepoint. cData collected after period 2 day 2 for one patient were excluded from analyses due to a minor
protocol deviation
Figure 2 Comparison of platelet aggregation to arachidonic acid and bleeding time. BL, baseline.
Nomultiplicity adjustment was performed because there is
only one formal primary hypothesis (on vorapaxar) and one
primary end point of interest (bleeding time). Thus, all the
p values showed in this article were unadjusted nominal p
values.
A natural log-transformation was applied to all the bleed-
ing time data as well as PT and aPTT prior to analyses,
and final results were reported on the original scale after
back-transformation. Data for TRAP-, AA-, and ADP-induced
platelet aggregation were not transformed. The assumption
of normality was tested by the Shapiro-Wilk statistics and
an examination of the Q-Q plot. Although minor departure
for normality was observed in the bleeding time data based
on the Shapiro-Wilk statistics (p < 0.05), further examina-
tion of the residuals from the Q-Q plot suggested that the
deviation was relatively minor, thus the log-transformation
was retained as the primary analysis. The homogeneity of
variance assumption was tested by the Levene’s test and
was satisfied (p > 0.050).
RESULTS
Demographics
Thirty-six healthy male (N = 31) and female (N = 5) sub-
jects were enrolled into the study at a single clinical site.
The mean age of the subjects was 41 years (range, 21–54
years). Twenty-seven subjects (75%) were black, eight sub-
jects (22%) were white, and one (3%) was of mixed race.
All 36 subjects completed the study; however, data collected
after period 2 day 2 for one patient were excluded from anal-
yses due to a minor protocol deviation.
Pharmacokinetics
Table 2 and Figure 2 summarize the vorapaxar PK results.
On day 7 of the vorapaxar treatment periods, the geomet-
ric mean Cmax levels ranged from 54 to 67 ng/mL and the
geometric mean C24 levels ranged from 44 to 51 ng/mL. On
days 6 and 7 of the vorapaxar treatment periods, the geo-
metric mean Ctrough levels ranged from 47 to 51 ng/mL and
48 to 51 ng/mL, respectively.
Platelet aggregation
Table 3 and Figure 2 summarize the platelet aggrega-
tion assessment results. TRAP-induced platelet aggrega-
tion was inhibited 93.6% (90% CI = 90.3–96.9) relative
to baseline after 7 days of vorapaxar treatment alone and
was unchanged after 7 days of treatment with vorapaxar
coadministered with aspirin. AA-induced platelet aggre-
gation was inhibited 92.4% (90% CI = 88.0–96.8) rela-
tive to baseline after 7 days of aspirin treatment alone.
Clinical and Translational Science
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Table 3 TRAP-, AA-, and ADP-induced platelet aggregation (% inhibition) 24
h following 7 days of treatment with vorapaxar or aspirin, and 24 h following
7 days treatment with vorapaxar + aspirin
TRAP-induced platelet aggregation
Treatment No.
LS mean
(95% CI) %
inhibition
of platelet
aggregation
Aspirin 18 10.3 (6.99–13.6)
Vorapaxar + aspirin 35 93.7 (92.8–94.6)
Vorapaxar 18 93.6 (90.3–96.9)
Treatment comparison Difference (90% CI) p value
Vorapaxar vs. aspirin 83.3 (79.4–87.3) <0.001
Vorapaxar + aspirin vs. aspirin 83.4 (80.5–86.4) <0.001
Vorapaxar + aspirin vs.
vorapaxar
0.1 (–2.8 to 3.0) 0.949
AA-induced platelet aggregation
Treatment No.
LS mean
(95% CI) %
inhibition
of platelet
aggregation
Aspirin 18 92.4 (88.0–96.8)
Vorapaxar + aspirin 35 92.0 (90.1–93.9)
Vorapaxar 18 –1.2 (-5.7 to 3.2)
Treatment comparison Difference (90% CI) p value
Vorapaxar vs. aspirin –93.6 (-98.9 to -88.4) <0.001
Vorapaxar + aspirin vs. aspirin –0.4 (-4.4 to 3.7) 0.877
Vorapaxar + aspirin vs.
vorapaxar
93.3 (89.2–97.3) <0.001
ADP-induced platelet aggregation
Treatment No.
LS mean
(95% CI) %
inhibition
of platelet
aggregation
Aspirin 18 10.2 (6.1–14.3)
Vorapaxar + aspirin 35 9.4 (6.8–12.0)
Vorapaxar 18 –2.6 (–6.7 to 1.6)
Treatment comparison Difference (90% CI) p value
Vorapaxar vs. aspirin –12.8 (–17.1 to -8.4) <0.001
Vorapaxar + aspirin vs. aspirin –0.8 (–3.9 to 2.3) 0.655
Vorapaxar + aspirin vs.
vorapaxar
11.9 (8.8–15.1) <0.001
AA, arachidonic acid; CI, confidence interval; LS mean, least squares mean;
TRAP, thrombin receptor agonist peptide.
Coadministration of aspirin with vorapaxar did not detectably
alter this interaction. ADP-induced platelet aggregation was
unaffected by vorapaxar treatment as compared with base-
line. ADP-induced platelet aggregation was inhibited mod-
estly by aspirin treatment relative to baseline either in the
absence (10.2% inhibition; 90% CI = 6.09–14.3) or presence
(9.39% inhibition; 90% CI = 6.78–12.0) of vorapaxar.
Coagulation parameters
Neither vorapaxar nor aspirin nor their combined administra-
tion altered aPTT or PT (data not shown).
Table 4 Bleeding time at baseline, 24 h following 7 days of treatment with
vorapaxar or aspirin and 24 h following 7 days treatment with vorapaxar +
aspirin
Treatment No.
LS mean (95%
CI) bleeding
time (min)
Baseline 36 5.09
(4.56–5.68)
Vorapaxar 18 5.12
(4.37–6.00)
Aspirin 17 6.71
(5.70–7.90)
Vorapaxar + aspirin 35 7.52
(6.54–8.63)
Treatment comparison GMR (90% CI) p value
Vorapaxar vs. baseline 1.01 (0.88–1.15) 0.933
Vorapaxar + aspirin vs.
aspirin
1.12 (0.96–1.30) 0.219
Aspirin vs. baseline 1.32 (1.15–1.51) 0.002
Vorapaxar + aspirin vs.
vorapaxar
1.47 (1.26–1.70) < 0.001
CI, confidence interval; GMR, geometric mean ratio, transformed back from
log-scale; LS mean, least squares mean.
Bleeding time
Table 4 summarizes the bleeding time assessment results.
Aspirin alone increased least squares (LS) mean bleeding
time from 5.09 min to 6.71 min (p = 0.002), whereas vora-
paxar had no effect, with an LS mean bleeding time of
5.12 min (p = 0.933). Aspirin and vorapaxar together demon-
strated an LS mean bleeding time of 7.52 min, different from
vorapaxar alone (p < 0.001). There was a slight numerical
increase in bleeding time with vorapaxar coadministered with
aspirin compared with aspirin alone, but the difference was
not significant (p = 0.219). Bleeding time results were not
available for one of 18 subjects in the aspirin group.
Safety
No subject reported a bleeding-related adverse event.
DISCUSSION
Vorapaxar administered in addition to standard of care
reduces thrombotic cardiovascular events in patients with
a history of myocardial infarction or with peripheral artery
disease.1,2 Although its PAR-1-mediated mechanism of
action provides patient benefit when coadministered with
standard of care, the potential exists that bleeding time, due
to the inhibition of this hemostatic mechanism, may be pro-
longed. A properly conducted capillary bleeding time assess-
ment is considered a reproducible and sensitive method
to measure the effects of treatment on the initial phase
of hemostasis, formation of a platelet plug. The present
study in healthy volunteers evaluated the potential for
vorapaxar to prolong bleeding time using a recognized stan-
dard methodology.
The present study assessed steady-state bleeding time by
a regimen producing, after 5 days’ dosing, plasma exposures
of vorapaxar equivalent to those at steady-state. Popula-
tion PKmodel-based simulations assuming the demographic
www.wileyonlinelibrary/cts
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characteristics (gender, race, and body weight) of subjects
enrolled in this study show that subjects receiving a 2.5 mg
once-daily dose are expected to have steady-state average
Cmax and trough plasma concentration (Cmin) of 64.8 ng/mL
(95% CI = 58.3–72.2 ng/mL) and 42.2 ng/mL (95% CI =
36.7–48.6 ng/mL), respectively. The plasma concentrations
of vorapaxar on days 6 and 7 measured in each period of
the present study (Cmax = 54–67 ng/mL; Ctrough day 6 and 7
= 47–51 ng/mL in this study) confirmed attainment of appro-
priate steady-state conditions. Results from previous phase I
clinical trials of vorapaxar in healthy volunteers also support
that day 6 and 7 vorapaxar concentrations in this study are
consistent with steady-state concentrations for 2.5 mg once-
daily dose.5,6
The inhibition of platelet aggregation wasmeasured by var-
ious methods to confirm the anticipated action of the admin-
istered aspirin and vorapaxar. Administration of vorapaxar
alone resulted in inhibition of TRAP-induced platelet aggre-
gation without an effect on either ADP- or AA-mediated acti-
vation of platelet aggregation, consistent with vorapaxar’s
PAR-1-specific mechanism of action. Aspirin alone inhib-
ited AA-induced platelet aggregation and also, to a small
extent, that of ADP-induced aggregation. The combination of
vorapaxar and aspirin demonstrated these combined effects
without further alteration. These results were fully consistent
with the administered agents, demonstrating the engage-
ment of vorapaxar at the PAR-1 receptor in subjects treated
with vorapaxar for 7 days in the presence or absence of
aspirin as well as inhibition of the thromboxane B2 receptor
after administration of aspirin in the presence or absence of
vorapaxar.
The AA-induced platelet aggregation inhibition of 92.4%
(90% CI = 88.0–96.8) relative to baseline by aspirin treat-
ment alone was consistent with literature values (80% inhibi-
tion with 50-mg at steady-state, and 87% inhibition with 324-
mg aspirin at steady-state).7 Coadministration of aspirin with
vorapaxar did not detectably alter this effect. ADP-induced
platelet aggregation was unaffected by vorapaxar treatment
as compared with baseline. However, ADP-induced platelet
aggregation was inhibitedmodestly by aspirin treatment rela-
tive to baseline in the absence of vorapaxar (10.2% inhibition;
90%CI= 6.09–14.3) or presence of vorapaxar (9.39% inhibi-
tion; 90%CI= 6.78–12.0). Aspirin treatment is known to have
modest inhibitory effects on the aggregation sensitivity of the
ADP-receptor in response to stimulus by ADP, as demon-
strated by Payne et al.,8 who reported that healthy subjects
administered a single 150 mg dose of aspirin inhibited ADP-
induced platelet aggregation by 33% compared with an
aspirin-naive baseline. In this study, aPTT and PT values were
not changed upon administration of vorapaxar alone, aspirin
alone, or vorapaxar coadministered with aspirin over the 7-
day dosing intervals, consistent with observations during
development of vorapaxar and as has been demonstrated
for aspirin.7
With respect to the bleeding time assessment in this
study, aspirin 81 mg once-daily administered for 7 days
was included as a positive sensitivity control. A prior study9
showed a quantifiable prolongation in bleeding time following
administration of aspirin 81 mg once-daily for 7 days: GMR
(aspirin 81 mg/baseline) = 1.58; 90% CI = 1.33–1.88), and
was generally consistent, although slightly longer numeri-
cally compared with the prolongation observed in the present
study with aspirin 81 mg once-daily for 7 days: GMR (aspirin
81 mg/baseline = 1.32; 90% CI = 1.15–1.51). The bleeding
time GMR and 90% CI for vorapaxar alone compared with
baseline was 1.01 (90% CI = 0.88–1.15), which was within
the prespecified GMR equivalence bounds of 0.67 and 1.50.
Thus, it can be concluded that administration of vorapaxar to
steady-state plasma levels does not prolong bleeding time
significantly as compared with baseline. Similarly, the GMR
and 90% CI for vorapaxar coadministered with aspirin com-
pared with aspirin alone was 1.12 (90% CI = 0.96–1.30),
which was also within the prespecified GMR equivalence
bounds. Thus, it can be concluded that the bleeding time at
steady-state plasma vorapaxar coadministered with aspirin
81 mg once-daily for 7 days is similar to that of aspirin 81
mg once-daily for 7 days alone. The present findings are
in agreement with those of previously reported vorapaxar
single-dose rising and multiple-dose rising studies,10 which
used a puncture device rather than a cutting device for tem-
plate bleeding time assessment, and which demonstrated
that bleeding time was not meaningfully prolonged with vora-
paxar.
In conclusion, bleeding time assessed following adminis-
tration of aspirin to steady-state was significantly elevated
relative to bleeding time assessed at baseline. In contrast
to aspirin, bleeding time assessed following administration
of vorapaxar to steady-state was similar to that assessed
at baseline. Bleeding time assessed following administration
of steady-state vorapaxar coadministered with steady-state
aspirin was similar to that assessed for aspirin at steady-state
alone. The implications of these findings for clinical sponta-
neous or surgical bleeding await further analyses of clinical
trial data.
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